OTCMKTS:CLPBY Coloplast A/S (CLPBY) Stock Forecast, Price & News $12.40 -0.06 (-0.48%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$12.36▼$12.5150-Day Range$12.40▼$14.6552-Week Range$9.58▼$14.77Volume25,741 shsAverage Volume46,757 shsMarket Capitalization$26.78 billionP/E Ratio44.29Dividend Yield0.62%Price TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsDividendFinancialsHeadlinesSEC FilingsShort InterestProfileAnalyst RatingsChartCompetitorsDividendFinancialsHeadlinesSEC FilingsShort Interest Coloplast A/S MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthModerateBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth12.50%From $0.32 to $0.36 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Coloplast A/S. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of Coloplast A/S have been sold short.Short Interest Ratio / Days to CoverColoplast A/S has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coloplast A/S has recently decreased by 87.08%, indicating that investor sentiment is improving significantly. Previous Next 2.5 Dividend Strength Dividend YieldColoplast A/S pays a meaningful dividend of 1.40%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthColoplast A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Coloplast A/S is 27.50%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Coloplast A/S will have a dividend payout ratio of 21.39% next year. This indicates that Coloplast A/S will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLPBY. Previous Next 0.9 News and Social Media Coverage News SentimentColoplast A/S has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Coloplast A/S this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coloplast A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.10% of the stock of Coloplast A/S is held by institutions. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Coloplast A/S are expected to grow by 12.50% in the coming year, from $0.32 to $0.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coloplast A/S is 44.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.28.Price to Earnings Ratio vs. SectorThe P/E ratio of Coloplast A/S is 44.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.03.Price to Book Value per Share RatioColoplast A/S has a P/B Ratio of 25.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Coloplast A/S (OTCMKTS:CLPBY) StockColoplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.Read More Receive CLPBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address CLPBY Stock News HeadlinesJune 3, 2023 | americanbankingnews.comColoplast A/S (OTCMKTS:CLPBY) Rating Lowered to Equal Weight at Morgan StanleyMay 24, 2023 | americanbankingnews.comBrokerages Set Coloplast A/S (OTCMKTS:CLPBY) PT at $942.50June 10, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 19, 2023 | seekingalpha.comCLPBY Coloplast A/SMay 13, 2023 | msn.comColoplast AS - Class B (CLPBF) Declares $5.00 DividendMay 13, 2023 | americanbankingnews.comColoplast A/S (OTCMKTS:CLPBY) Downgraded by JPMorgan Chase & Co.May 11, 2023 | finance.yahoo.comColoplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23May 7, 2023 | cbsnews.comSam's Club May 2023 membership deal: Get one year of discounted gas, food and more for $35June 10, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 4, 2023 | americanbankingnews.comReviewing Coloplast A/S (OTCMKTS:CLPBY) & Bone Biologics (OTC:BBLG)May 1, 2023 | americanbankingnews.comColoplast A/S (OTCMKTS:CLPBY) Receives Average Recommendation of "Hold" from AnalystsApril 24, 2023 | finance.yahoo.comNew clinical study demonstrates significant improvement in pulmonary health and related symptoms when using Provox® Life™April 6, 2023 | americanbankingnews.comColoplast A/S (OTCMKTS:CLPBY) Given Average Rating of "Hold" by BrokeragesApril 5, 2023 | benzinga.comShort Volatility Alert: ColoplastMarch 30, 2023 | americanbankingnews.comColoplast A/S (OTCMKTS:CLPBY) Upgraded by Barclays to "Equal Weight"March 28, 2023 | cbsnews.comSam's Club March membership deal: Get one year of discounted gas, groceries and more for $25February 25, 2023 | finance.yahoo.comColoplast A/S: Coloplast Introduces Next-Generation Catheter; No Change to Our Fair Value EstimateNovember 18, 2022 | finance.yahoo.comColoplast Launches New Catheter in the U.S.November 15, 2022 | finance.yahoo.comColoplast appoints new President of its global Interventional Urology businessNovember 10, 2022 | finance.yahoo.comColoplast enters into Power Purchase Agreement with Better EnergyNovember 8, 2022 | finance.yahoo.comColoplast A/S - Announcement no. 12/2022 - Notice of Annual General MeetingNovember 7, 2022 | finance.yahoo.comColoplast A/S - Announcement no. 10/2022 - Annual Report 2021/22 & Remuneration Report 2021/22November 7, 2022 | finance.yahoo.comColoplast A/S - Announcement no. 11/2022 - Sustainability Report 2021/22November 7, 2022 | finance.yahoo.comColoplast A/S Announcement no. 9/2022 - Full-Year Financial Results 2021/22October 6, 2022 | finance.yahoo.comColoplast launches Saffron™ Fixation System for Prolapse RepairSeptember 12, 2022 | reuters.comColoplast A/SSeptember 8, 2022 | finance.yahoo.comColoplast A/S - Announcement no. 08/2022 - Financial Calendar 2022-23See More Headlines CLPBY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLPBY Company Calendar Last Earnings5/02/2019Ex-Dividend for 5/30 Dividend5/19/2023Dividend Payable5/30/2023Today6/10/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical Appliances & Supplies Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CLPBY Previous SymbolNASDAQ:CLPBY CUSIPN/A CIK1294325 Webwww.coloplast.com Phone(454) 911-1111FaxN/AEmployees12,500Year Founded1954Profitability EPS (Most Recent Fiscal Year)$0.28 Trailing P/E Ratio44.29 Forward P/E Ratio38.75 P/E GrowthN/ANet Income$585.21 million Net Margins21.62% Pretax MarginN/A Return on Equity69.30% Return on Assets33.77% Debt Debt-to-Equity Ratio0.02 Current Ratio1.29 Quick Ratio0.90 Sales & Book Value Annual Sales$2.76 billion Price / Sales9.70 Cash Flow$0.24 per share Price / Cash Flow52.47 Book Value$0.48 per share Price / Book25.83Miscellaneous Outstanding Shares2,160,000,000Free FloatN/AMarket Cap$26.78 billion OptionableNot Optionable Beta0.28 Social Links Key ExecutivesKristian VillumsenPresident & Chief Executive OfficerAllan RasmussenExecutive Vice President-Global OperationsAnders Lonning-SkovgaardChief Financial Officer & Executive Vice PresidentThomas BarfodDirector & ControllerPaul MarcunExecutive Vice President-GrowthKey CompetitorsZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNSTERISNYSE:STESmith & NephewNYSE:SNNDemant A/SOTCMKTS:WILYYView All Competitors CLPBY Stock - Frequently Asked Questions Should I buy or sell Coloplast A/S stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CLPBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares. View CLPBY analyst ratings or view top-rated stocks. How have CLPBY shares performed in 2023? Coloplast A/S's stock was trading at $11.63 at the beginning of 2023. Since then, CLPBY shares have increased by 6.6% and is now trading at $12.40. View the best growth stocks for 2023 here. Are investors shorting Coloplast A/S? Coloplast A/S saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,300 shares, a decline of 87.1% from the April 30th total of 17,800 shares. Based on an average daily volume of 55,300 shares, the days-to-cover ratio is presently 0.0 days. View Coloplast A/S's Short Interest. How were Coloplast A/S's earnings last quarter? Coloplast A/S (OTCMKTS:CLPBY) released its quarterly earnings data on Thursday, May, 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.07. The business had revenue of $688.45 million for the quarter. Coloplast A/S had a trailing twelve-month return on equity of 69.30% and a net margin of 21.62%. How often does Coloplast A/S pay dividends? What is the dividend yield for Coloplast A/S? Coloplast A/S announced a dividend on Wednesday, May 17th. Shareholders of record on Monday, May 22nd will be paid a dividend of $0.0475 per share on Tuesday, May 30th. This represents a yield of 1.34%. The ex-dividend date of this dividend is Friday, May 19th. Read our dividend analysis for CLPBY. Is Coloplast A/S a good dividend stock? Coloplast A/S (OTCMKTS:CLPBY) pays an annual dividend of $0.08 per share and currently has a dividend yield of 1.40%. The dividend payout ratio is 27.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CLPBY will have a dividend payout ratio of 21.39% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for CLPBY. What is Coloplast A/S's stock symbol? Coloplast A/S trades on the OTCMKTS under the ticker symbol "CLPBY." How do I buy shares of Coloplast A/S? Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Coloplast A/S's stock price today? One share of CLPBY stock can currently be purchased for approximately $12.40. How much money does Coloplast A/S make? Coloplast A/S (OTCMKTS:CLPBY) has a market capitalization of $26.78 billion and generates $2.76 billion in revenue each year. The company earns $585.21 million in net income (profit) each year or $0.28 on an earnings per share basis. How many employees does Coloplast A/S have? The company employs 12,500 workers across the globe. How can I contact Coloplast A/S? Coloplast A/S's mailing address is HOLTEDAM 1-3, HUMLEBAEK G7, 3050. The official website for the company is www.coloplast.com. The company can be reached via phone at (454) 911-1111 or via email at dkebj@coloplast.com. This page (OTCMKTS:CLPBY) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coloplast A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.